A major new publication from the European Respiratory Society (ERS) ahead of its annual congress (Barcelona, 7 Sept 2013), shows that lung conditions are responsible for 1 in 10 of … continue reading
An international consortium of scientists today in an advanced online publication in the journal Nature revealed a comprehensive view of the altered genetic background of the type of lung cancer that is the most common cause of cancer deaths in humans.
An international team of scientists, supported in part by the National Human Genome Research Institute (NHGRI), one of the National Institutes of Health (NIH), announced that its systematic effort to map the genomic changes underlying lung cancer has uncovered a critical gene alteration not previously linked to any form of cancer. The research, published in the advance online issue of the journal Nature, also revealed more than 50 genomic regions that are frequently gained or lost in lung adenocarcinoma, the most common type of lung cancer in the United States.
GlaxoSmithKline [NYSE: GSK] announced approval by the U.S. Food and Drug Administration (FDA) for oral Hycamtin ® (topotecan) capsules for the treatment of relapsed small cell lung cancer (SCLC).
Researchers at Cold Spring Harbor Laboratory have discovered three genes that interact with cancerous results in 20 percent of lung cancers. The three genes are located next to each other on human chromosome 14 and two are known to play key roles in fetal lung development.
Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.
In clinical research, patients with advanced non-small cell lung cancer (NSCLC) that are classified as having a non-squamous histology achieve statistically significant higher survival when treated in the second-line setting with ALIMTA® (pemetrexed for injection) when compared to histologically-similar patients treated with docetaxel.
Eli Lilly and Company announced that it has submitted an application with the European Medicines Agency (EMEA) for centralised review of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, for the first-line treatment of advanced non-small cell lung cancer (NSCLC).
Biopharmaceutical researchers have found a protein in blood they say is linked to all stages of lung cancer but which rarely shows up in the blood of people without the disease. Testing for this protein might help physicians decide whether smokers or others at high risk for lung cancer should be referred for lung imaging, say investigators, who presented their findings today in Atlanta, Georgia at the American Association for Cancer Research’s second International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Variations in a gene that influences the innate immune system?the part of the immune system that provides short-term protection against infection?may be associated with lung cancer survival.